After graduating in Medicine in 2006, Pietro Ameri completed the residency and received his PhD in 2014 at the University of Genova, Italy. He is now Associate Professor in Cardiovascular Diseases at the University of Genova / IRCCS San Martino Policlinic Hospital, where he directs the Heart Failure and Pulmonary Hypertension clinical programs, as well as a translational research laboratory. Prof. Ameri's primary interest is heart failure. He is also involved in cardio-oncology, especially with respect to the interplay between heart failure, cancer, and anti-cancer therapies. If he was asked to bring a book, a movie, and a song with him on a desert island, today he would pick The catcher in the rye, The big Lebowski, and Hey you.
CV Hossein Ardehali
Hossein Ardehali, MD, PhD, FACC, FAHA, FISHR
Thomas D. Spies Professor of Cardiac Metabolism
Professor of Medicine – Cardiology
Professor of Pharmacology
Director, Medical Scientist Training Program
Director, Center for Molecular Cardiology
Northwestern University School of Medicine
Immediate Past President, American Society for Clinical Investigation (ASCI)
Deputy Editor, Journal of Clinical Investigation (JCI)
CV Aarti Asnani
Dr. Asnani is the Director of Cardio-Oncology at Beth Israel Deaconess Medical Center (BIDMC) in Boston. She is a principal investigator in the BIDMC CardioVascular Institute, an Associate Member of the BIDMC Cancer Research Institute, and an Assistant Professor at Harvard Medical School. Dr. Asnani graduated from Duke University with a degree in chemistry and French, followed by a medical degree from Duke University School of Medicine. She completed her research training in the laboratories of Robert Gerszten, MD and Randall Peterson, PhD at Massachusetts General Hospital. Dr. Asnani leads a basic and translational research program that aims to develop protective strategies for patients with heart toxicity secondary to cancer therapy. Her research has been funded by the NIH, American Heart Association, and Breast Cancer Alliance. In parallel with her research program, her clinical practice focuses on patients who have both cancer and cardiovascular disease.
CV Raúl Córdoba
Dr Raul Cordoba is Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. He obtained his Bachelor of Medicine degree from the Autonomous University of Madrid and went on to specialise in haematology at the University Hospital La Princesa, Madrid. He first started his research in the field of lymphoid neoplasms, achieving his Master’s degree in Molecular Oncology from the Spanish National Cancer Research Centre, Madrid, and his PhD from the Department of Medicine at the Autonomous University of Madrid.Dr Cordoba participated in the first edition of the Certificate of Competence in Lymphoma at Ulm, Germany. He is currently the Principal Investigator for the Haematology Programme of START Madrid-FJD, a unit dedicated exclusively to Phase I trials in oncology.He is the chair of the EHA-Scientific Working Group of “”Aging and Hematology”” of the European Hematology Association (EHA). He has participated as a co-author of the 2022 Guidelines of Cardio-Oncology of the European Society of Cardiology.
Rudolf A. de Boer
CV Rudolf A. de Boer
Professor Rudolf A. de Boer
Cardiologist & Chair of Cardiology
Erasmus MC Rotterdam
Rudolf de Boer is Chair and Professor of Cardiology at the Erasmus MC, Rotterdam, the Netherlands. His clinical and research interests include heart failure, with a specialty in cardiogenetics, cardio-oncology, obesity, diabetes, HFpEF and biomarkers. He has served as the president of the Heart Failure Working Group of the Dutch Society of Cardiology, been a board member of the Heart Failure Association (HFA), and currently is the President of the Dutch Cardiac Society. He has been an associate editor of the European Journal of Heart Failure and now is an associate editor of the European Heart Journal (section Heart Failure).
Head of the Medical Oncology Section of the Hospital Universitario La Paz in Madrid and Director of the Innovation Unit of the Hospital La Paz Institute for Health Research - IdiPAZ. Associate Professor of Oncology at the Autonomous University of Medicine of Madrid and Co-Director of the Chair of Innovative Medicine.
The main areas of scientific and healthcare interest are focused on the molecular biology of lung cancer and other thoracic tumors, the study of predictive factors of response to cancer treatments using high-throughput techniques and the study of etiopathogenic factors of the disease and supportive care. In particular, he has participated in the clinical development of EGFR and ALK inhibitors, antiangiogenic drugs and immunotherapy in lung cancer. Dr. de Castro has published more than 200 articles in international journals and is a member of ASCO, IASLC and ESMO. He is currently secretary of the board of SEOM (Spanish Society of Medical Oncology).
Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical in Thunder Bay, Ontario.
In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer with a focus on new drug development. In 2008, Dr. Dent, she established a multidisciplinary cardio-oncology clinic in Ottawa and in 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries.
Dr. Dent is recognized for her efforts in the evaluation of novel cancer treatments for breast cancer while gaining a better understanding of the impact of these treatments on cardiovascular health. She is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on cancer therapy related cardiovascular toxicity. She continues to work and build relationships with global organizations interested in cardio-oncology including: European Society of Medical Oncology, American College of Cardiology, the American Heart Association, and the American Society of Clinical Oncology. Dr. Dent currently serves as President of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives.
In September 2018, Dr. Dent accepted a staff position at Duke University as a breast cancer medical oncologist, Co-Director of Cardio-Oncology, and Associate Director of Breast Cancer Clinical Research. Twitter: @sdent_duke
CV Daniel Engelbertsen
Daniel Engelbertsen, PhD, Associate Professor
Cardiovascular Research - Cellular Metabolism and Inflammation
Dept. of Clinical Sciences, Malmö
Lund University, Sweden
Dr. Engelbertsen is an Associate Professor and group leader at Cardiovascular Research - Cellular Metabolism and Inflammation, Lund University, Sweden. His research is focused on understanding mechanisms that regulate T-cell activation in atherosclerotic plaques, with a particular focus on the role of co-inhibitory receptors and cardio-oncology. Dr. Engelbertsen was previously a postdoctoral fellow at Brigham and Women’s Hospital, Harvard Medical School, in the lab of Professor Andrew H. Lichtman before returning to Lund University to start his own research lab.
Maria F. Velasco
CV Maria Fernandez Velasco
Group leader of Cardiovascular Physio-pathology at Institute of Research University Hospital La PAZ, IdiPAZ
Twitter: @Mfvlorenzo; @IdiPAZScience
CV Rodolphe Fischmeister
Rodolphe Fischmeister is Director of Research at INSERM and founder of the Laboratory of Signalling and Cardiovascular Pathophysiology - Inserm unit 1180. His lab is based at the Faculty of Pharmacy of the University of Paris-Saclay. After graduating as an electrical engineer from Supélec in 1978, he moved first to theoretical biology for doctoral studies (PhD in 1980) and then to cellular physiology during the 2 1/2 years of postdoctoral studies at Dalhousie University (Halifax, Canada) and Emory University (Atlanta, GA, USA). He returned to France in 1983 and became a researcher at INSERM. He obtained a Doctorat d’Etat ès Sciences in 1987. His main research interests are directed toward physiological and pathophysiological aspects of neuroendocrine regulation of heart function, cardiac membrane receptors and their signalling cascades, and cellular control of cardiac ion channels.
Dr. Fischmeister is an elected member of a number of professional organisations, member of the Academia Europaea, Past-President of the European Section of the ISHR. He has received several prizes and awards: Jeanne-Philippe Beziat Cardiology Prize 2012, Alain Castaigne Prize 2014, Grand prix de Cardiologie Lamonica 2016, Peter Harris Distinguished Scientist award of the ISHR 2022.
CV Michael Fradley
Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as both the section chief of the consultative cardiology section and the medical director of the Thalheimer Center for Cardio-Oncology at the University of Pennsylvania. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. Prior to joining the University of Pennsylvania, he established the cardio-oncology program at Moffitt Cancer Center and the University of South Florida in Tampa. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He has published more than 90 manuscripts and is a frequently invited speaker at international meetings. He has served as the co-chair of the Global Cardio-Oncology Summit in both 2018 and 2021and is a member of the IC-OS (International CardioOncology Society) Board of Directors.
CV Valentín Fuster
The cardiologist Valentín Fuster currently combines roles as General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid and President of the Cardiovascular Institute and Physician-in-Chief at Mount Sinai Medical Center in New York.
Dr. Fuster, who is also Editor in Chief of the Journal of American College of Cardiology (JACC), is a world-renowned figure whose vision for health promotion has defined the roadmap to defeating the unsustainable pandemic of cardiovascular disease.
Dr. Fuster has been named Doctor Honoris Causa by thirty-five universities, and his immense scientific contribution is reflected in an H factor of 218 (Google Scholar). Among his many achievements, Dr. Fuster is the only cardiologist to have received the highest research awards from the four leading international cardiology organizations: the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the Interamerican Society of Cardiology.
Jose Javier Fuster
CV Jose Javier Fuster
Jose Javier Fuster, PhD
José Fuster is Assistant Professor and Group Leader at the Spanish National Center for Cardiovascular Research (CNIC) in Madrid (Spain), where he is also the Coordinator of the Scientific Program on Novel Mechanisms of Atherosclerosis. He previously held faculty positions at Boston University and the University of Virginia in the USA. His research group at CNIC investigates the interplay between the hematopoietic and the cardiovascular systems in the context of cardiovascular disease, with a particular focus on the pathophysiology of atherosclerosis and heart failure. He is considered a leading expert in the role of age-related clonal hematopoiesis in cardiovascular disease. His work on this topic has been published in prestigious journals, including research articles in Science, the Journal of the American College of Cardiology, Nature Cardiovascular Research and Cell Reports. Among other awards, he was awarded the Young Investigator Award of the European Atherosclerosis Society.
CV Carlos Galán
Carlos Galán obtained his degree in Veterinary Medicine in 2011 in Universidad Complutense de Madrid. After that, in 2012, he coursed a research master at the same university about echocardiography in small animals. Before starting his PhD he obtained a second master in molecular biomedicine at Universidad Autonoma de Madrid about ischemia/reperfusion injury-targeted therapies in large animal models under the direction of Borja Ibáñez in CNIC.
In 2014 he started his PhD in the same laboratory, studying the cardiotoxic side effect of anthracyclines, focused in cardiac magnetic resonance and novel potential therapeutic strategies. During this stage, he did a predoctoral stage at Harvard School of Medicine learning mitochondrial transplantation in-vivo techniques under the supervision of Dr. James McCully. After finishing his PhD he also obtained the master in Research Methodology and Statistics by Universidad Autónoma de Barcelona.
Since 2020, he have been working as postdoctoral researcher in Borja Ibanez’s group in the ERC MATRIX Project, deciphering different research gaps from mechanism to translational therapies regarding cardio-oncology and other cardiovascular diseases.
Social network: Twitter: @cgalanarriola In: https://www.linkedin.com/in/carlos-gal%C3%A1n-arriola-8b4931232/
Dr. Ine´s Garci´a-Lunar is a doctor in Cardiology, a specialist in non-invasive cardiac imaging and a researcher at the National Center for Cardiovascular Research (CNIC). After completing MD and Cardiology training in Madrid, she further specialized in advanced cardiovascular imaging at Mount Sinai Hospital, New York (2012). Currently she combines her clinical work in Cardiology & Cardiac Imaging with her work as a researcher and emerging group leader at CNIC. She has >10-year experience in translational research at CNIC with relevant original publications in the field of Non-Invasive Imaging and Cardiovascular Prevention.
CV Alessandra Ghigo
Alessandra Ghigo, PhD
Associate Professor of Applied Biology
University of Torino
Department of Molecular Biotechnology and Health Sciences
Alessandra Ghigo is Associate Professor of Applied Biology at the Department of Molecular Biotechnology and Health Sciences of the University of Torino. She is best known for her work on the crosstalk between phosphoinositide 3-kinase (PI3K) and cyclic nucleotide signaling pathways in heart failure and arrhythmias. Her recent interest is the comprehension of the molecular mechanisms underlying the cardiotoxicity of anti-cancer therapies, with a major focus on the contribution of PI3K enzymes. She is author of more than 90 publications in highly reputed journals, including Science, Science Translational Medicine and Circulation. She is invited speaker in prestigious conferences including meetings of the American Heart Association, the European Society of Cardiology and the International Society for Heart Research. She is co-founder and Scientific Advisor of Kither Biotech, a biotechnology company developing PI3K inhibitors for the treatment of respiratory diseases.
Since 2004 she is heading of the Human Genotyping Unit, as part of the Spanish National Genotyping Center (www.cegen.org). Her research activity at the CNIO is focused on the identification of genetic markers influencing cancer susceptibility and drug response. Gonzalez-Neira´s work is focused on breast cancer, but extends to several other cancer types such childhood cancers, lung cancer and more recently testicular cancer. She has been involved since 2006 in the Breast Cancer Consortium (BCAC) and in the last ten years she has been involved with other BCAC partners as work package leader in two European projects focused on the identification of breast cancer genes: the Collaborative Oncological Gene-environment Study (COGS) and the Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) project. Using genotyping and next generation sequencing technologies, these two projects, which involved the analysis of thousands of samples from different countries, have allowed identifying many relevant risk alleles and results have been published in high-impact journals.
Currently, she is executive broad Member of the Spanish Society for Pharmacogenetics and Pharmacogenomics (SEFF) and the National Representative and Board Member in the European Association for Predictive, Preventive and Personalized Medicine (EPMA).
She plays an important role in fundraising through national and international competitive projects and in the communication and establishment of effective collaborations with other researchers and institutions. In recent years, she has focused her efforts to facilitate the incorporation of genomics into clinical practice, working on the implementation of the genetic information in the NHS
CV Borja Ibáñez
Borja Ibáñez (Madrid, 1975) combines research activities as Scientific Director of the Spanish National Center for Cardiovascular Research (CNIC) with clinical activities as interventional cardiologist at the University Hospital Fundación Jiménez Díaz.
He was trained in Spain and in USA (Mount Sinai Heart, NY). His research is at the verge of basic and clinical arena, mainly in the fields of MI, heart failure and lately to cancer therapy-induced cardiotoxicity. He is the co-PI of the large PESA project, focused on primary prevention of atherosclerosis.
He is PI of several multicenter clinical trial. He served as the Chairperson of the 2017 European Society of Cardiology (ESC) STEMI Clinical Practice Guidelines and is Chairperson of the forthcoming ESC guidelines for Acute Coronary syndromes.
He is PI coordinator of several national and international projects, including H2020-funded grants, highlighting an active ERC consolidator grant called “MATRIX” (Novel mitochondria-targeted therapies for anthracycline-induced cardiotoxicity), and a H2020-HEALTH project called “RESILIENCE”.
He has published more than 350 scientific publications in high-impact journals. His H-index (scholar) is 73, and his works have received more than 50,000 citations.
He has received numerous awards for his scientific merits, including the Banco de Sabadell, Constantes y Vitales, Princesa de Girona, and Fundación Jesús Serra among others.
CV Richard Kitsis
Richard N. Kitsis, M.D.
Professor of Medicine (Cardiology) and Cell Biology
The Dr. Gerald and Myra Dorros Chair in Cardiovascular Disease
Director, Wilf Family Cardiovascular Research Institute
Albert Einstein College of Medicine
New York City, USA
The Kitsis laboratory studies: (a) fundamental mechanisms of cell death; and (b) roles of cell death in human disease (heart disease, diabetes, and cancer) and aging. The lab has elucidated basic aspects of cell death biology including mechanisms that mediate apoptosis and regulated forms of necrosis, molecular interconnections among these programs, and connections with mitochondrial biology and cellular senescence. We have also created drugs to manipulate some of these processes. The overarching goal of this work is to create a unified model of cell death that integrates multiple individual cell death programs.
CV Teresa López-Fernández
Teresa López-Fernández is a clinical investigator and senior consultant cardiologist at the University Hospital of La Paz in Madrid, Spain. Dr López-Fernández specialises in cardiac imaging and cardio-oncology. Dr López-Fernández coordinates the Cardio-Oncology Clinic at the University Hospital of La Paz. She is the founder and president of the Spanish Cardio-Oncology Working Group of the Spanish Society of Cardiology (SEC). She is also vice-president of the International Cardio-Oncology Society (ICOS) and was elected president of the ESC Council for Cardio-Oncology. Dr López-Fernández is co-chair of the ESC Guidelines on Cardio-Oncology 2022. Her current research interests focus on the diagnosis and prevention of cardiotoxicity.
CV Pilar Martín
Pilar Martín Fernández is Assistant Professor at the Spanish National Cardiovascular Research Center (CNIC) in Madrid. Dr. Martin leads a line of research in the field of Cardio-Immunology, focused on the role of T cells and microRNAs in the pathophysiology of myocarditis, atherosclerosis and myocardial infarction in preclinical models and humans. Her contributions to the cardio-immunology field as a senior author have been published in high-impact journals, including the New England Journal of Medicine, Circulation, the Journal of Clinical Investigation, European J Heart Failure, or the Journal of Autoimmunity. Her group has developed two patents: "Method for diagnosing cardiomyopathies" and "Kit for the diagnosis of acute myocarditis".
I did my PhD in Molecular and Cellular Biology at the University of Navarra in Pamplona, focused on adult stem cell regeneration for myocardial infarction. After a first in-site postdoc, I enjoyed a 4-year postdoc in the Stevens Group (Imperial College London), specializing in cardiovascular tissue engineering. In 2018, I became group leader (PI) for the Cardiac Tissue Engineering Group at Cima University of Navarra and coordinator of the Regenerative Medicine network. My team´s research focuses in building human cardiovascular tissues for regeneration, but also and very strongly, towards drug testing and disease modelling. We employ human induced pluripotent stem cell (hiPSC) technology alongside biomaterials and additive manufacturing technologies (i.e. 3D printing) to build from small- to human-scale cardiac tissues. Given their translational potential, we have started developing models and testing systems for cardio oncology, which can advance the understanding and detection of anti-cancer therapies unwanted cardiac adverse effects.
Wouter C. Meijers MD PhD FESC FHFA
(Experimental) Cardiology Department
Erasmus MC, Rotterdam, The Netherlands
Dr. Wouter C. Meijers obtained his medical degree at the Maastricht University. After which he was granted a PhD position at the (Experimental) cardiology department of prof. de Boer and prof. van Veldhuisen, which he later on defended cum laude. His translational studies focused on heart failure and more specifically on cardio-oncology. He pioneered on the reciprocal relationship between cancer and heart failure. Furthermore, he co-founded the more specialized field of cardio-immuno-oncology. He obtained several national and international grands and awards which helped him to pursue his research career. He was the first Dutch cardiologist in training whom performed a post-doctoral fellowship in the field of cardio-oncology at the Vanderbilt University Medical Center in Nashville, Tennessee, USA with prof. Moslehi. He is currently fellow of both the European Society of Cardiology as the Heart Failure Association. He recently transferred within the Netherlands to Rotterdam, the Erasmus Medical Center to further train himself within (advanced) heart failure and cardio-oncology and to further expand his own research group.
CV Tienush Rassaf
Tienush Rassaf is Director and Chair of the Department of Cardiology and Vascular Medicine at the University Hospital Essen, Germany, and Vice-Dean of Research of the Medical Faculty in Essen. Prof Rassaf is an interventional cardiologist with a research focus on cardioprotection in acute myocardial infarction and myocardial ischemia/reperfusion- injury. He is founding member and has been chairmen of the working group ‘Cardiooncology’ of the German Cardiac Society (DGK). On of his current research interests focus on the prevention of cardiotoxicity.
Education and job positions
Research group leader “Molecular Cardiology”, since 2021
Department Cardiology and Angiology, Hannover Medical School, Germany
• Pathomechanisms in Peripartum Cardiomyopathy
• Cardiotoxic anti-cancer therapies
Postdoctoral fellow Molecular Cardiology (Prof. Hilfiker-Kleiner) (2012-2020) and Habilitation (2023) in Experimental Cardiology “Molecular pathomechanisms in peripartum cardiomyopathy”, Hannover Medical School, Germany
Studies in Biology, Leibniz University Hannover; Diploma Biology, Department of Physiological Chemistry (Prof. Naim), University of Veterinary Medicine Hannover, Germany (2001-2006)
Research interests and activities
Molecular signaling pathways leading to heart failure, pathomechanisms in peri/postpartum cardiomyopathy, preclinical mouse animal models, cardiotoxic side effects of anti-cancer therapies
Fadi N. Salloum, PhD, FAHA, FAPS
Professor of Medicine (Cardiology)
Natalie N. and John R. Congdon Sr. Endowed Chair in Cardiology
Associate Chair for Research, Department of Internal Medicine
Associate Director of Research Mentoring & Preclinical Science, VCU Health Pauley Heart Center
School of Medicine
Virginia Commonwealth University
Dr. Salloum has served as PI or co-investigator on numerous National Institutes of Health, American Heart Association, and Industry-funded grants and currently leads a multi-disciplinary basic science and translational research program funded by the NIH and AHA for the last 13 years, with the most recent funding of the prestigious 7-year NHLBI R35 award through 2027 (R35HL155651). The lab’s focus is on the role of novel or ‘repurposed’ drugs in cardioprotection against cancer therapy-related injury and adverse cardiac remodeling/failure through suppression of sterile inflammation, mitochondrial dysfunction, and protein aggregates that may lead to cardiomyopathy.
Twitter: @SALLOUMFN LinkedIn: Fadi N. Salloum
CV Pilar Sepúlveda
Dr. Sepúlveda obtained in 1995 her PhD in Chemistry (Biochemistry) from the University of Valencia (Spain). After a postdoctoral stay in the field of autoimmune cardiomyopathy as a Marie Curie fellow (Pasteur Institute, Paris, France, 1997-2000), She returned to Valencia where She started her career in the cardiovascular cell therapy field (2002). Since 2004, Dr. Sepúlveda has been working as principal investigator through a Miguel Servet followed by I3SNS Program (2010). In 2014 She became the coordinator of the Regenerative Medicine and Heart Transplantation Unit at Health Research Institute Hospital La Fe, an accredited group of 30 people including basic and clinical researchers. Dr. Sepúlveda has published more than 80 articles, reviews and book chapters. Since 2009, her interest is in the field of extracellular vesicles derived from mesenchymal stem cells. More recently, She focused her interest in cardiotoxicity. In particular, She has developed cellular models of cardiotoxicity using patient-specific iPSC and She is involved in the understanding the role of miR-4732-3p in the risk of cardiotoxicity after anthracyclines treatment. Dr. Sepúlveda is also a regular member of the European Society of Cardiology Working Group on Cardiovascular Regenerative and Reparative Medicine from April 2018, CIBER-CV since 2019 and belongs to the European Platform of women scientists (EPWS) from december 2017. https://orcid.org/0000-0001-6071-7431. SCOPUS Author ID: 35369402200
Carlo Gabriele Tocchetti
CV Carlo Gabriele Tocchetti
Prof. Carlo Gabriele Tocchetti is currently Associate Professor of Medicine in the Department of Translational Medical Sciences, Federico II University, Naples, Italy since 2014, where he is Director of the Internal Medicine Unit for cancer patients and has established himself as a HF basic and clinical investigator. Prof Tocchetti is President, International Cardio-Oncology Society (ICOS) Italy Chapter, Fellow of the HFA, Chair of the Basic Science Section of the HFA, and Board member of the ESC Council on Cardio-Oncology.
The main goal of his lab is to explore pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic HF, genetic and inflammatory cardiomyopathies, Pulmonary Hypertension and RV dysfunction, and HF due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.
Peter van der Meer
CV Peter van der Meer
Professor Peter van der Meer, MD, PhD
University Medical Center Groningen, Netherlands
Peter van der Meer is a cardiologist, chair of the Department of Experimental Cardiology and director of the Coronary Care Unit at University Medical Center Groningen. He is also a Professor of Heart Failure and Translational Cardiology at the University of Groningen.
Professor van der Meer received both his MD and PhD cum laude from the University of Groningen, and completed a postdoctoral fellowship at Harvard Medical School, Boston, MA, USA. He authored >300 manuscripts, has an H-index of 77 and was member of the 2022 ESC CardioOncology guidelines. He is a member of several steering committees of large phase 3 trials. His research is funded by national and international grants including an ERC StG and CoG grant. His research group consists of PhD students and post-docs with various backgrounds (biologists, medical doctors and biomedical-engineers) working on translational research topics to bridge the gap between bench and bedside. Professor van der Meer’s research focusses on understanding the susceptibility to develop heart failure and on exploring novel treatment targets and therapies.